Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks
Pharmacogenetic information in Swiss drug labels - a systematic analysis
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
ID
4611136
Author(s)
Jeiziner, C.; Suter, K.; Wernli, U.; Barbarino, J. M.; Gong, L.; Whirl-Carrillo, M.; Klein, T. E.; Szucs, T. D.; Hersberger, K. E.; Meyer Zu Schwabedissen, H. E.
Pharmacogenetic information in Swiss drug labels - a systematic analysis
Journal
Pharmacogenomics Journal
Volume
21
Number
4
Pages / Article-Number
423-434
Abstract
Implementation of pharmacogenetics (PGx) and individualization of drug therapy is supposed to obviate adverse drug reactions or therapy failure. Health care professionals (HCPs) use drug labels (DLs) as reliable information about drugs. We analyzed the Swiss DLs to give an overview on the currently available PGx instructions. We screened 4306 DLs applying natural language processing focusing on drug metabolism (pharmacokinetics) and we assigned PGx levels following the classification system of PharmGKB. From 5979 hits, 2564 were classified as PGx-relevant affecting 167 substances. 55% (n = 93) were classified as "actionable PGx". Frequently, PGx information appeared in the pharmacokinetics section and in DLs of the anatomic group "nervous system". Unstandardized wording, appearance of PGx information in different sections and unclear instructions challenge HCPs to identify and interpret PGx information and translate it into practice. HCPs need harmonization and standardization of PGx information in DLs to personalize drug therapies and tailor pharmaceutical care.
